Log In
Print
BCIQ
Print
Print this Print this
 

TSX-002

  Manage Alerts
Collapse Summary General Information
Company TesoRx Pharma LLC
DescriptionOral pro-liposomal formulation of unmodified testosterone
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II
Standard IndicationHypogonadism
Indication DetailsTreat hypogonadism
Regulatory Designation
Partner Aspen Pharmacare Holdings Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$95.0M

$15.0M

$80.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today